Oncotarget cover image

CDK9 Inhibitors: A Promising Combination Partner in Treating Hematological Malignancies

Oncotarget

00:00

Exploring CDK-9 Inhibitors in Hematological Malignancies

Exploring the potential of CDK-9 inhibitors in combination therapies for treating hematological malignancies, with a focus on their mechanism of action and positive clinical outcomes observed in high-grade lymphoma patients.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app